Research Topics
| P J ClementsSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAHPhilip J Clements
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Ann Rheum Dis 71:249-52. 2012....- Assessment of gastrointestinal involvementP J Clements
Division of Rheumatology Medicine, Rm 32 59, 1000 Veteran Avenue, UCLA School of Medicine, Los Angeles, California, USA
Clin Exp Rheumatol 21:S15-8. 2003..A minimal core set of variables has been identified to be used in clinical investigation for the assessment of esophagus, stomach, small intestine, colon and anorectum involvement in scleroderma patients... - Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosisPhilip J Clements
Department of Medicine, University of California, Los Angeles, 90095, USA
Arthritis Rheum 50:1909-17. 2004..This study was undertaken to investigate the utility of high-resolution computed tomography (HRCT) of the chest, in comparison with bronchoalveolar lavage (BAL), in the diagnosis of alveolitis in these patients... - High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements
Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
Semin Arthritis Rheum 33:249-63. 2004..To review important findings, or lessons, that were learned about measures of response, design, conduct, and analysis of a randomized, controlled trial (RCT), even though the trial failed to demonstrate efficacy of d-penicillamine... - Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements
Divisions of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Ann Rheum Dis 66:1641-7. 2007..This report examines the differences at baseline and over 12 months between patients with limited versus diffuse cutaneous SSc who participated in the Scleroderma Lung Study... - Differences in presentation of younger and older systemic sclerosis patients in clinical trialsH H Weng
Amgen Inc, Thousand Oaks, CA, USA
Clin Exp Rheumatol 28:S10-4. 2010..To compare the characteristics of younger and older subjects with diffuse cutaneous systemic sclerosis (SSc) entering clinical trials... - The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements
UCLA School of Medicine, Los Angeles, California 90095-1670, USA
Arthritis Rheum 44:653-61. 2001..The HAQ DI is a self-administered questionnaire that SSc patients can complete easily and rapidly and that gives the practicing physician important information about prognosis, patient status, and changes in disease course over time... - Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trialsSogol Amjadi
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
Arthritis Rheum 60:2490-8. 2009.... - Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung StudyDinesh Khanna
David Geffen School of Medicine, University of California, Los Angeles, USA
Arthritis Rheum 52:592-600. 2005.... - Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FASTNihal Fathi
David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Curr Rheumatol Rep 9:144-50. 2007.... - Systemic sclerosis and bilateral lung transplantation: a single centre experienceR Saggar
Division of Pulmonary and Critical Care Medicine, Dept of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1690, USA
Eur Respir J 36:893-900. 2010..AR rates may be significantly higher in the SSc group. Longer follow-up is necessary to determine the effects of gastrointestinal dysfunction and AR on late allograft function in SSc LTR... - Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Dinesh Khanna
David Geffen School at University of California, Los Angeles, CA, USA
J Rheumatol 36:2356-61. 2009..CRISS and EPOSS are being developed through the OMERACT process. Through Delphi process and literature review significant progress has been made for both indices, and prospective data are being collected... - Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trialsKaren Au
Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Curr Rheumatol Rep 11:111-9. 2009..A randomized double-blind controlled trial by the Scleroderma Lung Study Research Group is currently comparing the efficacy and safety of mycophenolate mofetil versus oral cyclophosphamide... - High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin
David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
Chest 134:358-67. 2008..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized... - Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna
David Geffen School of Medicine, and School of Public Health, University of California, Los Angeles, USA
Arthritis Rheum 60:1102-11. 2009.... - Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trialsMarian Kaldas
UCLA Olive View, Sylmar, CA, USA
Rheumatology (Oxford) 48:1143-6. 2009..Our objective was to evaluate the sensitivity of change over time of individual body sites used in the calculation of total MRSS... - Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract InstrumentDinesh Khanna
University of California, Los Angeles, CA, USA
Arthritis Rheum 61:1257-63. 2009..To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0)... - Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung StudyDinesh Khanna
Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 48:1537-40. 2009..Our objective was to assess minimally important difference (MID) for Mahler's Transition Dyspnoea Index (TDI) in SLS... - Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trialPuja P Khanna
Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 49:955-9. 2010.... - Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three casesDinesh Khanna
David Geffen School of Medicine at UCLA, 1000 Veteran Avenue, Room 32 59 Rehabilitation Building, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 49:1184-8. 2010..EF is a rare fibrosing disorder that may involve skin and internal organs. Current therapies include moderate- to high-dose glucocorticoids with or without use of immunosuppressives... - Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trialsDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Clin Exp Rheumatol 28:S55-62. 2010..Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review... - Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosisVijay Bodukam
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
Rheumatology (Oxford) 50:330-4. 2011..0 instrument; and (ii) to explore which GI-specific symptom scales are associated with depressed mood in patients with SSc... - Oral cyclophosphamide for active scleroderma lung disease: a decision analysisDinesh Khanna
Division of Rheumatology, School of Public Health, University of California at Los Angeles, Los Angeles, CA 90095, USA
Med Decis Making 28:926-37. 2008..Also, the long-term balance of risk and benefit remains unclear... - Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trialDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
J Rheumatol 35:466-8. 2008..We assessed if HAQ-DI scores are different when calculated with and without aids/devices, and if apparent responsiveness changes when scored in these 2 ways... - Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin
University of California at Los Angeles, Los Angeles, USA
N Engl J Med 354:2655-66. 2006.... - Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin
Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
Am J Respir Crit Care Med 176:1026-34. 2007..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear... - Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trialDinesh Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, Los Angeles, California, USA
J Rheumatol 32:832-40. 2005.... - Assessing disease progression using a composite endpointWeng Kee Wong
Department of Biostatistics, University of California at Los Angeles, CA, USA
Stat Methods Med Res 16:31-49. 2007..In addition, we propose desirability functions to monitor patients' disease improvement when the outcomes are all continuous. This method offers several possible advantages over existing methods for measuring patients' improvement... - Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna
Division of Immunology, Department of Medicine, University of Cincinnati, ML 0563, Cincinnati, OH 45267 0563, USA
Ann Rheum Dis 65:1325-9. 2006..To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc)... - Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot studyTien I Karleen Su
University of Southern California, Los Angeles, CA 90095 1670, USA
Arthritis Rheum 60:3821-30. 2009..To assess the safety and efficacy of rapamycin in the treatment of diffuse systemic sclerosis (SSc; scleroderma)... - A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patientsH G Kim
Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA 90024 2926, USA
Clin Exp Rheumatol 28:S26-35. 2010.... - Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
Ann Rheum Dis 67:703-9. 2008..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)... - A longitudinal analysis of humor coping and quality of life in systemic sclerosisErin L Merz
SDSU UCSD Joint Doctoral Program in Clinical Psychology, San Diego, California, USA
Psychol Health Med 14:553-66. 2009.... - Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosisAntony T H Lin
Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA
Rheum Dis Clin North Am 29:409-26. 2003.... - Lymphomatoid granulomatosis: a rare mimicker of vasculitisSherry M Wu
Division of Rheumatology, Olive View-UCLA Medical Center, David Geffen School of Medicine, Los Angeles, CA 91342, USA
J Rheumatol 32:2242-5. 2005..We describe a case of LG with no pulmonary involvement, which was thought to be systemic vasculitis on the basis of multiorgan involvement and biopsy findings... - New onset systemic lupus erythematosus with pheochromocytomaAntony T H Lin
Department of Medicine, UCLA School of Medicine, USA
J Rheumatol 29:1334-7. 2002..This is a novel case of pheochromocytoma discovered at the onset of SLE, with resolution of SLE manifestations shortly after its removal... - Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patientsJason C Cole
Consulting Measurement Group, Huntington Beach, CA 91403, USA
Qual Life Res 15:1383-94. 2006..The goal of the current study was to examine the structural validity of the HAQ-DI in patients with systemic sclerosis (SSc, scleroderma) and to compare its performance with that in patients with RA... - Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna
University of Cincinnati, Cincinnati, Ohio 45267 0563, USA
Arthritis Rheum 56:1676-84. 2007..To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment... - Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosisVanessa L Malcarne
Department of Psychology, San Diego State University, CA 92120 4913, USA
J Rheumatol 34:359-67. 2007..To examine physician-assessed medical signs and patient-reported medical symptoms as correlates of 3 quality of life (QOL) outcomes in patients with systemic sclerosis (SSc): disability, pain, and psychosocial adjustment... - Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6Peter A Merkel
Arthritis Center, Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA
J Rheumatol 30:1630-47. 2003..The current level of validation of outcome measures in SSc is assessed according to the guidelines set forth by prior OMERACT meetings... - Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosisDinesh Khanna
Division of Immunology, Department of Internal Medicine, University of Cincinnati Medical Center, PO Box 670563, Cincinnati, OH 45267 0563, USA
Qual Life Res 16:1083-92. 2007.... - Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco
Marshfield Clinic, Wausau, Wisconsin, USA
Arthritis Rheum 46:2983-9. 2002..Although ACE inhibitors and dialysis are now readily available, SRC continues to be associated with poor survival (in this study, 50% of patients with SRC died)... - Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrumentDinesh Khanna
University of Cincinnati, The Veterans Affairs Medical Center, Cincinnati, Ohio, USA
Arthritis Rheum 57:1280-6. 2007..Gastrointestinal tract (GIT) involvement occurs in approximately 90% of patients with systemic sclerosis (SSc) and has a major impact on health-related quality of life (HRQOL). We developed an HRQOL instrument for persons with SSc...